more

Madrigal Pharmaceuticals (MDGL)

(Delayed Data from NSDQ)

$211.32 USD

+6.07 (2.96%)

Updated May 13, 2024 04:00 PM ET

After-Market: $211.37 +0.05 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

Top 37% (94 out of 251)

Industry: Medical - Drugs

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

NASH Scorecard Year to Date: The Winners and the Losers

by Ekta Bagri Published on November 29,2019

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

biotechs

Intercept (ICPT) Up on Q4 Revenue Beat, NASH Study in Focus

by Zacks Equity Research Published on March 01,2019

Intercept's (ICPT) Q4 revenues top estimates owing to strong Ocaliva sales, driven by sales force expansion and growth in its foreign geographies.

biotechs

Intercept Reports Positive Top-Line Data for NASH, Shares Up

by Zacks Equity Research Published on February 20,2019

Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.

biotechs

Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails

by Zacks Equity Research Published on February 12,2019

Gilead (GILD) suffers a setback as its phase III study on pipeline candidate, selonsertib, in patients with compensated cirrhosis (F4) due to NASH fails to meet goal.

biotechs

Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018

by Zacks Equity Research Published on December 28,2018

Intercept (ICPT) outperforms the broader market in 2018 as lead drug Ocaliva recovers, following the company's efforts to increase awareness about the updated label.

biotechs

Intercept (ICPT) Gains on Earnings and Revenue Beat in Q3

by Zacks Equity Research Published on November 01,2018

Intercept's (ICPT) revenues beat estimates, owing to strong Ocaliva sales in the third quarter of 2018.

5 Best Biotech Stocks to Buy In October

by Zacks Equity Research Published on October 01,2018

Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October

Viking Therapeutics Liver Candidate Passes Test, Shares Soar

by Zacks Equity Research Published on September 19,2018

Viking Therapeutics (VKTX) pipeline candidate, VK2809, achieves statistically significant reduction in liver fat content and bad cholesterol levels in a phase II study, evaluated for NAFLD.

Madrigal (MDGL) Posts Narrower than Expected Loss in Q2

by Zacks Equity Research Published on August 07,2018

Madrigal (MDGL) posts narrower than expected loss in the second quarter of 2018.

MDGLPositive Net Change

Is a Beat in Store for Horizon Pharma (HZNP) in Q2 Earnings?

by Zacks Equity Research Published on August 06,2018

During the second-quarter earnings call, Horizon Pharma (HZNP) will focus on the performance of business units along with that of Actimmune and Krystexxa and update on teprotumumab's development.

Jazz Pharma (JAZZ) Q2 Earnings Coming Up: What's in Store?

by Zacks Equity Research Published on August 06,2018

Jazz's (JAZZ) Xyrem will likely continue to do well in the second quarter. Supply constraints will continue to hurt sales of Erwinaze.

What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?

by Zacks Equity Research Published on August 06,2018

Merck's (MKGAF) Healthcare and Life Science segments are expected to drive sales in Q2. However, higher operating expense to support Bavencio and Mavenclad launch is expected to weigh on performance.

Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers

by Zacks Equity Research Published on August 03,2018

Intercept (ICPT) gains on a better-than-expected second quarter as loss narrows and sales surpass estimates on a significant recovery in Ocaliva.

Company News For Jun 4, 2018

by Zacks Equity Research Published on June 04,2018

Companies in the news are: MDGL,LULU,ULTA,GM

Madrigal's NASH Study Data Encouraging, Stock Skyrockets

by Zacks Equity Research Published on June 01,2018

Madrigal Pharmaceuticals' (MDGL) thyroid hormone receptor, MGL-3196, achieves significantly sustained reduction in liver fat at week 36 in a phase II study evaluating it in NASH patients.

Company News For June 1, 2018

by Zacks Equity Research Published on June 01,2018

Companies In The News are: GM,DG,DLTR,MDGL